A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Th⦠(NCT05380388) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
Thailand36 participantsStarted 2027-01-01
Plain-language summary
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3. MIST3's primary objectives are to assess the safety of the PvRII/Matrix-M vaccine candidate in healthy adult Thai volunteers and to establish whether the PvRII/Matrix-M vaccine can demonstrate a reduced parasite multiplication rate in vaccinated volunteers compared to a controlled group (placebo vaccine) in a blood-stage controlled human malaria infection model. This study will recruit up to 36 eligible healthy volunteers aged 20-55 in Thailand at the Faculty of Tropical Medicine, Mahidol University. Eighteen volunteers will receive three doses of the PvRII/Matrix-M candidate vaccine, and 18 volunteers will receive three doses of the placebo vaccine. Safety and immunogenicity will be evaluated after each dose as per protocol. Approximately four weeks after receiving the third vaccination, 24 volunteers will undergo blood-stage CHMI with Plasmodium vivax. The volunteers will be monitored closely as in-patients in the Hospital for Tropical Diseases and treated according to the Research Proposal Submission Form.
This study is funded by the UK Wellcome Trust. The grant reference number are Oxford/MORU: 212336/Z/18/Z and 212336/Z/18/A, and Mahidol University: 212336/A/18/Z and 212336/A/18/A
Who can participate
Age range20 Years β 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
β. Healthy Thai adults aged 20 to 55 years
β. Minimum educational level of high school or equivalent
β. Red blood cells positive for the Duffy antigen/chemokine receptor (DARC)
β. Women only: Must practice continuous effective contraception for the duration of the study period until 3 months post-challenge.
β. Agreement to refrain from blood donation during the study and for 1 year after the initiation of antimalarial treatment.
β. Willing to be admitted to the Hospital for Tropical Diseases for clinical monitoring as required by the protocol until antimalarial treatment is completed and their symptoms are settling, willing to take a curative antimalarial treatment following CHMI, and willing to reside in Bangkok and its vicinity for 2 months after malarial treatment initiation.
β. Able to read and write in Thai.
β. Provide written informed consent to participate in the trial
Exclusion criteria
What they're measuring
1
solicited local adverse event
Timeframe: 7 days following each vaccination
2
solicited systemic adverse event
Timeframe: 7 days following each vaccination
3
unsolicited adverse events
Timeframe: 28 days following each vaccination
4
safety laboratory measures
Timeframe: 28 days following each vaccination
5
serious adverse events
Timeframe: through study completion, an average of 1 year
. Positive malaria qPCR OR malaria film prior to vaccination and challenge
β. Presence of any medical condition (either physical or psychological) that, in the judgment of the investigator, would place the participant at undue risk (including the history of clinically significant contact dermatitis) or interfere with the results of the study (e.g., underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition)
β. Presence of chronic disease or chronic use of medication
β. Prior receipt of other investigational vaccine which is likely to impact the interpretation of the trial data as assessed by the Investigator.
β. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection, asplenia, history of splenectomy, recurrent severe infections, and chronic infection
β. Immunosuppressant medication within the past 6 months preceding enrolment (D0) or plan to use during the study (inhaled and topical steroids are allowed)
β. History of allergic disease or reactions likely to be exacerbated by malaria infection
β. Female participant who is pregnant as evidenced by positive beta-human chorionic gonadotropin (Ξ²-HCG) test, or who is lactating or planning pregnancy during the course of the study.